Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting

Xiaofu Zhu; Eitan Amir; Gurmit Singh; Mark Clemons; Christina Addison

doi:10.1016/j.jbo.2014.01.001

Journal of Bone Oncology (Mar 2014)

Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting

Xiaofu Zhu,
Eitan Amir,
Gurmit Singh,
Mark Clemons,
Christina Addison

Affiliations

Xiaofu Zhu: Division of Medical Oncology, Ottawa Hospital and Faculty of Medicine, University of Ottawa, Ottawa, Canada
Eitan Amir: Division of Medical Oncology and Hematology, University of Toronto and Princess Margaret Hospital, Toronto, Canada
Gurmit Singh: Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada
Mark Clemons: Division of Medical Oncology, Ottawa Hospital and Faculty of Medicine, University of Ottawa, Ottawa, Canada
Christina Addison: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada

DOI: https://doi.org/10.1016/j.jbo.2014.01.001
Journal volume & issue: Vol. 3, no. 1
pp. 1 – 4

Abstract

Read online

The annual Bone and The Oncologist New Updates (BONUS 8) conference focuses on the current understanding and dilemmas in the treatment and prevention of bone metastasis in cancer, as well as novel research on bone homeostasis and cancer-induced bone loss. We present commentaries from experts for their own take on where they feel the field of bone-targeted therapies for metastatic breast cancer is moving, or needs to move, if we are to make further progress.

Published in Journal of Bone Oncology

ISSN: 2212-1374 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the musculoskeletal system; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.journals.elsevier.com/journal-of-bone-oncology/

About the journal

Abstract

Keywords